Results for:(76 found)
Jan 2, 2013 12:07PM on Top StocksBy TheStreet Staff

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his biotechnology forecast for the new year.

Dec 27, 2012 11:51AM on Top StocksBy Minyanville.com

Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.

Dec 14, 2012 10:10AM on Top StocksBy Jim Cramer

Neither party seems to understand the consequences of what Congress does to American businesses.

Dec 10, 2012 5:35PM on Top StocksBy Minyanville.com

Analysts expect pomalidomide will win US approval in February, adding a potential blockbuster treatment to the biotech's drug lineup.

Tags: CELG
Nov 21, 2012 12:04PM on Top StocksBy MSN Money Partner

Skechers is upgraded to 'positive,' and Yum Brands is initiated with an 'outperform.'

Nov 20, 2012 1:17PM on Top StocksBy TheStreet Staff

Clinical trials, drug launches and FDA approval decisions fill the calendar for these companies at the start of the new year.

Nov 9, 2012 12:33PM on Top StocksBy MSN Money Partner

Groupon is downgraded to 'equal weight,' while Isis Pharmaceuticals is upgraded to 'outperform.'

Oct 2, 2012 11:28AM on Top StocksBy TheStreet Staff

The company's Abraxane delays tumor growth in patients with advanced melanoma.

VIDEO ON MSN MONEY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

MARKET DISPATCHES

No more Dispatches; here's where to find market news

The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.

More